Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | TK2 | O00142 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idoxuridine SCHEMBL846580 | 1.00 | TK1 (0.67) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Doxribtimine SCHEMBL11444539 | 0.86 | TK1 (0.87) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL3477 | 0.82 | TK1 (0.43) | TK1LMNAADRA1ABLM | |
| SCHEMBL28129115 | 0.82 | TK1 (0.43) | TK1LMNAADRA1ABLM | |
| Idoxuridine SCHEMBL13252710 | 0.82 | TK1 (1.00) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Idoxuridine SCHEMBL6519051 | 0.82 | TK1 (1.00) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Idoxuridine SCHEMBL9951400 | 0.82 | TK1 (1.00) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Idoxuridine SCHEMBL21585076 | 0.82 | TK1 (1.00) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Idoxuridine SCHEMBL4426782 | 0.82 | TK1 (1.00) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| Idoxuridine SCHEMBL37714 | 0.82 | TK1 (1.00) | TK1LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3470108-A1 | TREATMENT MEDIUM DELIVERY DEVICE FOR DELIVERY OF TREATMENT MEDIA TO THE EYE | Mati Therapeutics Inc. (US) | 2019-04-17 | — | — | EP | claimed |
| EP-3372205-A1 | LACRIMAL IMPLANT DETECTION | Mati Therapeutics Inc. (US) | 2018-09-12 | — | — | EP | claimed |
| EP-2276471-B1 | COMPOSITE LACRIMAL INSERT AND RELATED METHODS | MATI THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | claimed |
| EP-2010096-B1 | NASOLACRIMAL DRAINAGE SYSTEM IMPLANTS FOR DRUG THERAPY | MATI THERAPEUTICS INC (US) | 2017-07-19 | — | — | EP | claimed |
| CN-102105137-B | Composite lacrimal implants and related methods | QLT PLUG DELIVERY INC | 2015-01-07 | — | — | CN | claimed |
| CN-102105137-A | Composite lacrimal implants and related methods | QLT PLUG DELIVERY INC | 2011-06-22 | — | — | CN | claimed |
| EP-2276471-A2 | COMPOSITE LACRIMAL INSERT AND RELATED METHODS | QLT Plug Delivery, Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| EP-1671624-B1 | Delivery device for a controlled drug release of an active agent into the posterior section of the eye | SURMODICS INC (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009134371-A2 | COMPOSITE LACRIMAL INSERT AND RELATED METHODS | QLT PLUG DELIVERY, INC. (US) | 2009-11-05 | — | — | WO | claimed |
| EP-1671624-A1 | Delivery device for a controlled drug release of an active agent into the posterior section of the eye | SurModics, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-12029683-B2 | Ocular implant and delivery system | ALCON INC. (CH) | 2024-07-09 | — | — | US | disclosed |
| US-20240207091-A1 | DRUG DELIVERY IMPLANTS WITH BI-DIRECTIONAL DELIVERY CAPACITY AND METHODS OF USING SAME | GLAUKOS CORP (US) | 2024-06-27 | — | — | US | disclosed |
| US-11998481-B2 | Methods and compositions for iontophoretic drug delivery to the eye | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11992551-B2 | Implants with controlled drug delivery features and methods of using same | GLAUKOS CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4371535-A2 | OCULAR IMPLANT | Alcon Inc. (CH) | 2024-05-22 | — | — | EP | disclosed |
| WO-2005009482-A2 | DEVICES, SYSTEMS AND METHODS FOR MINIMALLY INVASIVE SURGERY OF THE THROAT AND OTHER PORTIONS OF MAMMALIAN BODY | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050019371-A1 | Controlled release bioactive agent delivery device | SURMODICS, INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004098565-A2 | IMPLANTABLE CONTROLLED RELEASE BIOACTIVE AGENT DELIVERY DEVICE | SURMODICS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004066871-A2 | RESERVOIRS WITH SUBRETINAL CANNULA FOR SUBRETINAL DRUG DELIVERY | DOHENY RETINA INSTITUTE (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004028477-A2 | METHODS FOR TREATMENT AND/OR PREVENTION OF RETINAL DISEASE | SURMODICS, INC. (US) | 2004-04-08 | — | — | WO | disclosed |